NASDAQ:CNSP CNS Pharmaceuticals (CNSP) Stock Price, News & Analysis $7.25 +0.15 (+2.15%) As of 12:10 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CNS Pharmaceuticals Stock (NASDAQ:CNSP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CNS Pharmaceuticals alerts:Sign Up Key Stats Today's Range$7.02▼$7.6450-Day Range$2.13▼$7.1552-Week Range$1.90▼$34.80Volume102,852 shsAverage Volume1.02 million shsMarket Capitalization$5.88 millionP/E RatioN/ADividend YieldN/APrice Target$20.00Consensus RatingHold Company Overview CNS Pharmaceuticals, Inc., headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment. Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development. WP1066 is in preclinical stages with plans to progress to early-phase clinical studies, targeting patients who have limited treatment options due to the highly immunosuppressive nature of central nervous system tumors. Together, these candidates reflect the company’s strategy to address both direct cytotoxic and immune-mediated approaches to brain cancer therapy. Under the leadership of Chairman and Chief Executive Officer Howard J. Robin, CNS Pharmaceuticals completed its initial public offering on the NASDAQ Capital Market under the symbol CNSP. The company conducts clinical trials across North America and collaborates with academic and research institutions to support its development programs. With a dedicated focus on unmet needs in neuro-oncology, CNS Pharmaceuticals aims to advance its pipeline toward regulatory approvals and ultimately provide new treatment options for patients with life-threatening brain tumors.AI Generated. May Contain Errors. Read More CNS Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreCNSP MarketRank™: CNS Pharmaceuticals scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingCNS Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCNS Pharmaceuticals has a consensus price target of $20.00, representing about 175.0% upside from its current price of $7.27.Amount of Analyst CoverageCNS Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about CNS Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of CNS Pharmaceuticals is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CNS Pharmaceuticals is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCNS Pharmaceuticals has a P/B Ratio of 1.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about CNS Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.19% of the float of CNS Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCNS Pharmaceuticals has a short interest ratio ("days to cover") of 1.89, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CNS Pharmaceuticals has recently increased by 7.97%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCNS Pharmaceuticals does not currently pay a dividend.Dividend GrowthCNS Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.28 News SentimentCNS Pharmaceuticals has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for CNS Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for CNSP on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows3 people have added CNS Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CNS Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders0.01% of the stock of CNS Pharmaceuticals is held by insiders.Percentage Held by Institutions14.02% of the stock of CNS Pharmaceuticals is held by institutions.Read more about CNS Pharmaceuticals' insider trading history. Receive CNSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CNS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNSP Stock News HeadlinesWhat's going on with CNS Pharmaceuticals stock on Wednesday?May 6 at 3:42 PM | msn.comCNS Pharmaceuticals Announces Private Placement and Board ChangesMay 6 at 5:40 AM | theglobeandmail.comIran War Update: Trump’s Hand-Written Letter Reveals What Comes NextKosmos Energy is up 185% this year, Valaris has doubled, and Sky Quarry has surged 846% - and analyst Jim Rickards believes this is just the beginning for natural resource stocks. Rickards says a Trump action tied to Section 10 of Public Law 63-43 on May 15th could supercharge gains across energy, gold, silver, and critical metals - with the Financial Times estimating it could unleash $100 trillion in new wealth.May 8 at 1:00 AM | Paradigm Press (Ad)Why did CNSP stock surge 330% today?May 5 at 8:10 AM | msn.comCNS Pharmaceuticals (CNSP) soars 311.7% as investors react to $22.5M oversubscribed private placementMay 4, 2026 | quiverquant.comQCNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement FinancingMay 4, 2026 | finance.yahoo.comCNS Pharmaceuticals Inc.April 8, 2026 | barrons.comCNS Pharmaceuticals Unveils Strategic Pivot to Broader OncologyMarch 13, 2026 | theglobeandmail.comSee More Headlines CNSP Stock Analysis - Frequently Asked Questions How have CNSP shares performed this year? CNS Pharmaceuticals' stock was trading at $5.25 at the beginning of the year. Since then, CNSP shares have increased by 38.5% and is now trading at $7.2720. How were CNS Pharmaceuticals' earnings last quarter? CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) announced its quarterly earnings data on Tuesday, March, 31st. The company reported ($10.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($5.37) by $4.78. When did CNS Pharmaceuticals' stock split? CNS Pharmaceuticals's stock reverse split on Friday, February 21st 2025.The 1-50 reverse split was announced on Wednesday, February 19th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 20th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did CNS Pharmaceuticals IPO? CNS Pharmaceuticals (CNSP) raised $10 million in an initial public offering (IPO) on Friday, November 8th 2019. The company issued 2,125,000 shares at $4.00-$5.00 per share. Benchmark served as the underwriter for the IPO. How do I buy shares of CNS Pharmaceuticals? Shares of CNSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CNS Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that CNS Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO) and GE Aerospace (GE). Company Calendar Last Earnings3/31/2026Today5/08/2026Next Earnings (Estimated)5/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 As of 4 days ago, CNSP's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CNSP CIK1729427 Webwww.cnspharma.com Phone800-946-9185FaxN/AEmployees5Year Founded2017Price Target and Rating Average Price Target for CNS Pharmaceuticals$20.00 High Price Target$20.00 Low Price Target$20.00 Potential Upside/Downside+175.0%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($41.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.85 million Net MarginsN/A Pretax MarginN/A Return on Equity-164.56% Return on Assets-130.05% Debt Debt-to-Equity RatioN/A Current Ratio1.98 Quick Ratio1.98 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.29 per share Price / Book1.00Miscellaneous Outstanding Shares810,000Free Float811,000Market Cap$5.89 million OptionableNot Optionable Beta2.62 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:CNSP) was last updated on 5/8/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredOne executive order. The biggest wealth transfer of your lifetime.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | Sponsored‘Please’: OpenAI CEO Sam Altman Begs Small Company for HelpSpaceX 'Dark Energy' Replaces Foreign Oil For years, we've been told SpaceX is a rocket company. But accord...Altimetry | SponsoredIs the SpaceX IPO “Rigged?”The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CNS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CNSP Stock Alerts